These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28742529)

  • 1. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults.
    Bisson GP; Ramchandani R; Miyahara S; Mngqibisa R; Matoga M; Ngongondo M; Samaneka W; Koech L; Naidoo K; Rassool M; Kirui F; Banda P; Mave V; Kadam D; Leger P; Henestroza G; Manabe YC; Bao J; Kumwenda J; Gupta A; Hosseinipour MC;
    AIDS; 2017 Oct; 31(16):2217-2225. PubMed ID: 28742529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunistic diseases diminish the clinical benefit of immediate antiretroviral therapy in HIV-tuberculosis co-infected adults with low CD4+ cell counts.
    Worodria W; Ssempijja V; Hanrahan C; Ssegonja R; Muhofwa A; Mazapkwe D; Mayanja-Kizza H; Reynolds SJ; Colebunders R; Manabe YC
    AIDS; 2018 Sep; 32(15):2141-2149. PubMed ID: 30005014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-care C-reactive protein and risk of early mortality among adults initiating antiretroviral therapy.
    Chaisson LH; Semitala FC; Asege L; Mwebe S; Katende J; Nakaye M; Andama AO; Marquez C; Atuhumuza E; Kamya M; Cattamanchi A; Yoon C
    AIDS; 2019 Apr; 33(5):895-902. PubMed ID: 30649057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.
    Blanc FX; Sok T; Laureillard D; Borand L; Rekacewicz C; Nerrienet E; Madec Y; Marcy O; Chan S; Prak N; Kim C; Lak KK; Hak C; Dim B; Sin CI; Sun S; Guillard B; Sar B; Vong S; Fernandez M; Fox L; Delfraissy JF; Goldfeld AE;
    N Engl J Med; 2011 Oct; 365(16):1471-81. PubMed ID: 22010913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic or Test-Guided Treatment for Tuberculosis in HIV-Infected Adults.
    Blanc FX; Badje AD; Bonnet M; Gabillard D; Messou E; Muzoora C; Samreth S; Nguyen BD; Borand L; Domergue A; Rapoud D; Natukunda N; Thai S; Juchet S; Eholié SP; Lawn SD; Domoua SK; Anglaret X; Laureillard D;
    N Engl J Med; 2020 Jun; 382(25):2397-2410. PubMed ID: 32558469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
    Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
    N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial.
    Badje A; Moh R; Gabillard D; Guéhi C; Kabran M; Ntakpé JB; Carrou JL; Kouame GM; Ouattara E; Messou E; Anzian A; Minga A; Gnokoro J; Gouesse P; Emieme A; Toni TD; Rabe C; Sidibé B; Nzunetu G; Dohoun L; Yao A; Kamagate S; Amon S; Kouame AB; Koua A; Kouamé E; Daligou M; Hawerlander D; Ackoundzé S; Koule S; Séri J; Ani A; Dembélé F; Koné F; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatunde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Karcher S; Rouzioux C; Kouame A; Assi R; Bakayoko A; Domoua SK; Deschamps N; Aka K; N'Dri-Yoman T; Salamon R; Journot V; Ahibo H; Ouassa T; Menan H; Inwoley A; Danel C; Eholié SP; Anglaret X;
    Lancet Glob Health; 2017 Nov; 5(11):e1080-e1089. PubMed ID: 29025631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of antiretroviral therapy with tuberculosis treatment.
    Abdool Karim SS; Naidoo K; Grobler A; Padayatchi N; Baxter C; Gray AL; Gengiah T; Gengiah S; Naidoo A; Jithoo N; Nair G; El-Sadr WM; Friedland G; Abdool Karim Q
    N Engl J Med; 2011 Oct; 365(16):1492-501. PubMed ID: 22010915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of mortality among TB-HIV Co-infected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study.
    Sileshi B; Deyessa N; Girma B; Melese M; Suarez P
    BMC Infect Dis; 2013 Jul; 13():297. PubMed ID: 23815342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.
    Kroeze S; Ondoa P; Kityo CM; Siwale M; Akanmu S; Wellington M; de Jager M; Ive P; Mandaliya K; Stevens W; Boender TS; de Pundert ME; Sigaloff KCE; Reiss P; Wit FWNM; Rinke de Wit TF; Hamers RL
    AIDS; 2018 May; 32(8):1043-1051. PubMed ID: 29547445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
    Ross JM; Badje A; Rangaka MX; Walker AS; Shapiro AE; Thomas KK; Anglaret X; Eholie S; Gabillard D; Boulle A; Maartens G; Wilkinson RJ; Ford N; Golub JE; Williams BG; Barnabas RV
    Lancet HIV; 2021 Jan; 8(1):e8-e15. PubMed ID: 33387480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active tuberculosis is associated with worse clinical outcomes in HIV-infected African patients on antiretroviral therapy.
    Siika AM; Yiannoutsos CT; Wools-Kaloustian KK; Musick BS; Mwangi AW; Diero LO; Kimaiyo SN; Tierney WM; Carter JE
    PLoS One; 2013; 8(1):e53022. PubMed ID: 23301015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.
    Pac L; Horwitz MM; Namutebi AM; Auerbach BJ; Semeere A; Namulema T; Schwarz M; Bbosa R; Muruta A; Meya DB; Manabe YC
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):e69-76. PubMed ID: 25761234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
    Charalambous S; Grant AD; Innes C; Hoffmann CJ; Dowdeswell R; Pienaar J; Fielding KL; Churchyard GJ
    AIDS; 2010 Nov; 24 Suppl 5(0 5):S5-13. PubMed ID: 21079429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database.
    Han SH; Zhou J; Lee MP; Zhao H; Chen YM; Kumarasamy N; Pujari S; Lee C; Omar SF; Ditangco R; Phanuphak N; Kiertiburanakul S; Chaiwarith R; Merati TP; Yunihastuti E; Tanuma J; Saphonn V; Sohn AH; Choi JY;
    HIV Med; 2014 Feb; 15(2):77-85. PubMed ID: 23980589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial.
    Marcy O; Laureillard D; Madec Y; Chan S; Mayaud C; Borand L; Prak N; Kim C; Lak KK; Hak C; Dim B; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
    Clin Infect Dis; 2014 Aug; 59(3):435-45. PubMed ID: 24759827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher Mortality Despite Early Antiretroviral Therapy in Human Immunodeficiency Virus and Hepatitis B Virus (HBV)-Coinfected Patients With High HBV Replication.
    Kouamé GM; Boyd A; Moh R; Badje A; Gabillard D; Ouattara E; Ntakpe JB; Emième A; Maylin S; Chekaraou MA; Eholié SP; Zoulim F; Lacombe K; Anglaret X; Danel C;
    Clin Infect Dis; 2018 Jan; 66(1):112-120. PubMed ID: 29020361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.